Aptose Biosciences Inc. (APTO) Stock Price Down 8.2%
Aptose Biosciences Inc. (NASDAQ:APTO) was down 8.2% during trading on Wednesday . The company traded as low as $2.33 and last traded at $2.35, with a volume of 84,788 shares. The stock had previously closed at $2.56.
A number of equities research analysts have commented on APTO shares. Royal Bank Of Canada restated an “outperform” rating and set a $23.00 target price on shares of Aptose Biosciences in a research note on Saturday, June 25th. Roth Capital upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, June 9th. Canaccord Genuity restated a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Thursday, June 9th. Finally, Zacks Investment Research cut shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $12.30.
The stock’s 50 day moving average is $2.48 and its 200-day moving average is $2.65. The company’s market cap is $27.97 million.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.